My watch list
my.chemeurope.com  

my.chemeurope.com

With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Rilpivirine



Rilpivirine
Systematic (IUPAC) name
4-{[4-({4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl}
amino)pyrimidin-2-yl]amino}benzonitrile
Identifiers
CAS number 500287-72-9
ATC code  ?
PubChem 6451164
Chemical data
Formula C22H18N6 
Mol. mass 366.42 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 38 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

Rilpivirine (TMC278) is a diarylpyrimidine under under investigation as a treatment for HIV infection. It is a non-nucleoside reverse transcriptase inhibitor with many times the potency of current available agents in that class, such as efavirenz.[1][2]It is expected to be FDA approved as soon as 2009.[3]


References

  1. ^ Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B (2006). "Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects". AIDS 20 (13): 1721–6. doi:10.1097/01.aids.0000242818.65215.bd. PMID 16931936.
  2. ^ Pozniak A, Morales-Ramirez J, Mohap L et al. 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients. Oral abstract 144LB.
  3. ^ Steve Mitchell. HIV Market To Top 10 Billion Dollars. United Press International. April 11, 2007.
v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase Inbitors (NRTI)		Abacavir (ABC) • Didanosine • Emtricitabine° • Lamivudine (3TC)° • Stavudine • Zidovudine (AZT)° • Tenofovir° • Apricitabine† • Stampidine† • Elvucitabine† • Racivir† • Zalcitabine‡
Non-Nucleoside
Reverse Transcriptase Inhibitiors (NNRTI)		Efavirenz° • Nevirapine • Etravirine† • Rilpivirine† • Loviride‡ • Delavirdine‡
Protease Inhibitors (PI)Atazanavir • Darunavir • Fosamprenavir • Lopinavir° • Nelfinavir • Ritonavir • Saquinavir • Tipranavir • Amprenavir‡ • Indinavir‡
Entry/fusion inhibitorsEnfuvirtide • Maraviroc • Vicriviroc† • PRO 140†
Integrase inhibitorsRaltegravir • Elvitegravir†
Maturation inhibitorsBevirimat† • Vivecon™†
Combined formulationsCombivir • Atripla • Trizivir • Truvada • Kaletra • Epzicom
Other & experimental agentsFoscarnet • Synergistic enhancers • Epigallocatechin gallate • Portmanteau inhibitors • Globoidnan A • Griffithsin • Diarylpyrimidines • Calanolide A
†Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent. °Preferred first-line agent.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rilpivirine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE